MedCity News

MAY 23, 2023

As pharmaceutical reps are used less and less, the role of the MSL has become more prominent as a conduit between life sciences companies and external stakeholders for drug development.

Medical science 86

Medical science Medical Pharma Pharmaceutical 86

Clarivate

MARCH 8, 2023

In recent years, there has been an increased focus on real world evidence to advance medical science and improve patient quality of life. Biopharma companies are investing in the use of real world data (RWD) to accelerate innovation.

Patients 59

Patients Biopharma Medical science Electronics 59

pharmaphorum

DECEMBER 23, 2022

With these silos breaking down, biopharmas will have the opportunity to drive a more coordinated approach to HCP engagement using shared data and unified systems, while still maintaining compliance. Given the demand to deliver a steady stream of content to meet HCPs’ needs, pharma marketers must react, create, edit, and adapt quickly.

Marketing 99

Marketing Sales Medical Patients 99

PM360

NOVEMBER 21, 2022

Combined with the incentives provided by the Orphan Drug Act, a powerful dynamic is at play, ever further pushing the limits of what medical science can achieve. It’s also in these communities where biopharma finds the best opportunities to connect with their stakeholders. Accelerating the Path to Diagnosis and Treatment.

Patients 52

Patients Medicine Biopharma Media 52

Clarify Health

MAY 19, 2020

There is also a looming, time-sensitive reality that biopharma companies face once their products hit the market: they need to recoup the costs of development as quickly as possible before drug patents expire and generics threaten sales. sales, medical science liaisons, etc.).

Biopharma 52

Biopharma Physicians Marketing Prescription 52